Biotech Values

[DewDiligence]

>The SGP rates will get worse until the end of treatment, while the Vertex rates are final.<

The already reported VRTX dropout numbers cover the periods in each trial arm during which patients received Telaprevir; however, the dropout rates are not “final” until all therapy is completed, and the end-of-treatment dropout numbers have not yet been reported for the arms in PROVE-1 and PROVE-2 that have 48-weeks of therapy.

SVR data from the 24-week arms (but not the 48-week arms) will be presented Nov 5 and Nov 6 at AASLD (#msg-23267002).